- Conditions
- Connective Tissue Disease, Dissecting Aneurysm, Ehlers Danlos Syndrome, Marfan Syndrome, Nail Patella Syndrome
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1997 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 745–768
of 1,850
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Skin Laxity
- Interventions
- Advil, Lortab, Ulthera System Treatment
- Drug · Device
- Lead sponsor
- Ulthera, Inc
- Industry
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Atopic Dermatitis
- Interventions
- EDP1815, Placebo
- Drug
- Lead sponsor
- Evelo Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 421 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Fremont, California + 22 more
- Conditions
- Port Wine Stain
- Interventions
- ThermoVision A20M Infrared Camera, ScleroPLUS, 3D Digital Camera
- Device
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 3 Months to 17 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Atopic Dermatitis
- Interventions
- Not listed
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
- Conditions
- Hypermobile Ehlers-Danlos Syndrome, Hypermobile Spectrum Disorder, Ehlers-Danlos Syndrome
- Interventions
- Transcutaneous Auricular Neurostimulation
- Device
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Atopic Dermatitis
- Interventions
- TDM-180935 topical ointment 1.0%, TDM-180935 topical ointment 2.0%, TDM-180935 topical vehicle ointment 1, TDM-180935 topical vehicle ointment 2
- Drug
- Lead sponsor
- Technoderma Medicines Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 7
- States / cities
- Rolling Meadows, Illinois • Covington, Louisiana • New Brighton, Minnesota + 4 more
- Conditions
- Dermatitis, Atopic
- Interventions
- Abrocitinib 100 mg, Abrocitinib 200 mg, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 3,166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 156
- States / cities
- Birmingham, Alabama • Anaheim, California • Encinitas, California + 101 more
- Conditions
- Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
- Interventions
- Camoteskimab, Placebo
- Drug
- Lead sponsor
- Apollo Therapeutics Ltd
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Encinitas, California • Fountain Valley, California + 23 more
- Conditions
- Enchondromatosis
- Interventions
- Not listed
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Atopic Dermatitis
- Interventions
- EpiCeram Skin Barrier Emulsion, Desonide Cream 0.05%
- Device · Drug
- Lead sponsor
- Promius Pharma, LLC
- Industry
- Eligibility
- 3 Months to 12 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Chicago, Illinois • Winston-Salem, North Carolina + 2 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Glioblastoma Multiforme, Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Renal Cell Carcinoma
- Interventions
- DSP-7888 Dosing Emulsion
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Atlanta, Georgia • Lafayette, Indiana + 5 more
- Conditions
- Gout
- Interventions
- Uric Acid and Metabolite Monitor System (UR+AIMS) skin patch
- Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neurofibromatosis Type 1, Neurofibroma
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 20 Years to 99 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Vascular Ehlers-Danlos Syndrome
- Interventions
- Enzastaurin, Placebo
- Drug
- Lead sponsor
- Aytu BioPharma, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Englewood, Colorado
- Conditions
- Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus
- Interventions
- ATTO-1310, ATTO-1310 Placebo
- Drug
- Lead sponsor
- Attovia Therapeutics Inc
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 11
- States / cities
- Encinitas, California • Rocklin, California • Sacramento, California + 7 more
- Conditions
- Atopic Dermatitis
- Interventions
- AD printed educational materials, AD educational videos
- Other
- Lead sponsor
- Boston University
- Other
- Eligibility
- Up to 17 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Zoledronic Acid
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 3 Months to 17 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Wilmington, Delaware • Boise, Idaho + 7 more
- Conditions
- Dermatitis Atopic
- Interventions
- Amlitelimab
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 999 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Litchfield Park, Arizona • Bryant, Arkansas + 17 more
- Conditions
- Epidermolysis Bullosa
- Interventions
- allo-APZ2-OTS, Placebo
- Drug
- Lead sponsor
- RHEACELL GmbH & Co. KG
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Minneapolis, Minnesota
- Conditions
- Ehlers-Danlos Syndrome Hypermobility Type (hEDS)
- Interventions
- 3D scanned and 3D printed wrist hand orthosis
- Device
- Lead sponsor
- ELewis
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Lowell, Massachusetts
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Melanoma, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer
- Interventions
- ipilimumab
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 19 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Bisphosphonate, Setrusumab
- Drug · Biological
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 2 Years to 6 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 10 more
- Conditions
- Atopic Dermatitis (AD)
- Interventions
- CGB-500 with 0.5% tofacitinib, CGB-500 Ointment with 1% tofacitinib, Vehicle (placebo)
- Drug
- Lead sponsor
- CAGE Bio Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 16
- States / cities
- Fremont, California • Manhattan Beach, California • San Diego, California + 13 more